JP2012524092A - アモルファスアルファ−（ｎ−スルホンアミド）アセトアミド化合物の生物学的に利用可能なカプセル組成物 - Google Patents

アモルファスアルファ−（ｎ−スルホンアミド）アセトアミド化合物の生物学的に利用可能なカプセル組成物 Download PDF

Info

Publication number
JP2012524092A
JP2012524092A JP2012506123A JP2012506123A JP2012524092A JP 2012524092 A JP2012524092 A JP 2012524092A JP 2012506123 A JP2012506123 A JP 2012506123A JP 2012506123 A JP2012506123 A JP 2012506123A JP 2012524092 A JP2012524092 A JP 2012524092A
Authority
JP
Japan
Prior art keywords
capsule
peg
pharmaceutical composition
crystallization inhibitor
trifluoropentanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524092A5 (enExample
Inventor
サチン・チャンドラン
ラジェシュ・バブラル・ガンジー
ジャクアン・カラニ・レボンズ
ロバート・ケビン・パーローン
クリストファー・ピー・プライス
クリシュナスワミー・スリニバス・ラガーバン
イスマト・ウラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2012524092A publication Critical patent/JP2012524092A/ja
Publication of JP2012524092A5 publication Critical patent/JP2012524092A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2012506123A 2009-04-14 2010-04-13 アモルファスアルファ−（ｎ−スルホンアミド）アセトアミド化合物の生物学的に利用可能なカプセル組成物 Pending JP2012524092A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16906109P 2009-04-14 2009-04-14
US61/169,061 2009-04-14
PCT/US2010/030862 WO2010120755A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (2)

Publication Number Publication Date
JP2012524092A true JP2012524092A (ja) 2012-10-11
JP2012524092A5 JP2012524092A5 (enExample) 2013-03-28

Family

ID=42235859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506123A Pending JP2012524092A (ja) 2009-04-14 2010-04-13 アモルファスアルファ−（ｎ−スルホンアミド）アセトアミド化合物の生物学的に利用可能なカプセル組成物

Country Status (14)

Country Link
US (1) US8252821B2 (enExample)
EP (1) EP2419090B1 (enExample)
JP (1) JP2012524092A (enExample)
KR (1) KR20120022766A (enExample)
CN (1) CN102395361A (enExample)
AR (1) AR076305A1 (enExample)
AU (1) AU2010236602A1 (enExample)
BR (1) BRPI1015483A2 (enExample)
CA (1) CA2758847A1 (enExample)
EA (1) EA201101286A1 (enExample)
MX (1) MX2011010514A (enExample)
NZ (1) NZ595335A (enExample)
TW (1) TW201041609A (enExample)
WO (1) WO2010120755A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8934446B2 (en) 2009-10-02 2015-01-13 Lg Electronics Inc. Transmission method and device for a downlink reference signal
JP2022523371A (ja) * 2019-02-22 2022-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 医薬製剤

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
RU2734128C2 (ru) * 2010-12-16 2020-10-13 Плэтформ Брайтворкс Ту,Лтд Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям
DK3238709T3 (da) 2011-04-28 2020-09-28 Platform Brightworks Two Ltd Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
KR20210151880A (ko) 2019-04-11 2021-12-14 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피리딘 고리 함유 유도체
US20230310413A1 (en) * 2020-08-21 2023-10-05 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising a malt1 inhibitor and a mixture of polyethylene glycol with a fatty acid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
JP2005506990A (ja) * 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
JP2007535545A (ja) * 2004-04-28 2007-12-06 プロキャリア・インコーポレーテッド 難吸収性薬剤の経口投与のための製剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
PL326700A1 (en) 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
RU2202540C2 (ru) 1996-07-22 2003-04-20 Монсанто Компани Тиолсульфонамидные ингибиторы металлопротеазы
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
NZ512306A (en) 1999-01-27 2003-10-31 American Cyanamid Co Acetylenic sulfonamide thiol tace inhibitors
EP1159263A1 (en) 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
JP2006522126A (ja) 2003-03-31 2006-09-28 ワイス βアミロイド生産のフルオロ含有およびトリフルオロアルキル含有複素環スルホンアミド阻害物質およびその誘導体
CA2544350A1 (en) 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
CA2573372A1 (en) 2004-07-13 2006-01-19 F. Hoffmann-La Roche Ag Sulfonamide derivatives
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
JP2008523146A (ja) * 2004-12-14 2008-07-03 ワイス 神経変性障害の処置および予防のための５−ｈｔ６アゴニストの使用
US7687666B2 (en) 2006-02-17 2010-03-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
BRPI0707742A2 (pt) 2006-02-17 2011-05-10 Wyeth Corp processo para preparar um composto
CN101400349A (zh) * 2006-03-01 2009-04-01 罗斯坎普研究有限责任公司 抑制β-淀粉样蛋白产生的化合物
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
CN102088855A (zh) 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
MX2011009271A (es) 2009-03-19 2011-09-26 Bristol Myers Squibb Co Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide.
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
JP2005506990A (ja) * 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
JP2007535545A (ja) * 2004-04-28 2007-12-06 プロキャリア・インコーポレーテッド 難吸収性薬剤の経口投与のための製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014008835; Ｉｍｂｉｍｂｏ　ＢＰ: 'Ａｌｚｈｅｉｍｅｒ'ｓ　ｄｉｓｅａｓｅ：　gamma-ｓｅｃｒｅｔａｓｅ　ｉｎｈｉｂｉｔｏｒｓ' Ｄｒｕｇ　Ｄｉｓｃｏｖｅｒｙ　Ｔｏｄａｙ：　Ｔｈｅｒａｐｅｕｔｉｃ　Ｓｔｒａｔｅｇｉｅｓ Ｖｏｌ．５　Ｎｏ．３, 2008, ｐｐ．１６９-１７５ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8934446B2 (en) 2009-10-02 2015-01-13 Lg Electronics Inc. Transmission method and device for a downlink reference signal
US9313003B2 (en) 2009-10-02 2016-04-12 Lg Electronics Inc. Transmission method and device for a downlink reference signal
JP2022523371A (ja) * 2019-02-22 2022-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 医薬製剤

Also Published As

Publication number Publication date
NZ595335A (en) 2013-03-28
CN102395361A (zh) 2012-03-28
CA2758847A1 (en) 2010-10-21
WO2010120755A1 (en) 2010-10-21
TW201041609A (en) 2010-12-01
KR20120022766A (ko) 2012-03-12
US20100260837A1 (en) 2010-10-14
AU2010236602A1 (en) 2011-10-13
EA201101286A1 (ru) 2012-04-30
EP2419090B1 (en) 2013-02-13
EP2419090A1 (en) 2012-02-22
BRPI1015483A2 (pt) 2016-04-26
AR076305A1 (es) 2011-06-01
MX2011010514A (es) 2011-11-29
US8252821B2 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
JP2012524092A (ja) アモルファスアルファ−（ｎ−スルホンアミド）アセトアミド化合物の生物学的に利用可能なカプセル組成物
EP1441713B1 (en) Modified release tamsulosin tablets
ES2641637T3 (es) Composiciones farmacéuticas que comprenden ligandos del receptor sigma
JP5749247B2 (ja) 経口用徐放性固形製剤
CN101636152A (zh) 含有西洛他唑的控释制剂及其制备方法
EP2419086B1 (en) Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound
MXPA06000529A (es) Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
JPWO2011115067A1 (ja) 抗凝固剤の溶出改善方法
JPWO2010147169A1 (ja) 溶出性の改善された医薬組成物
ES2380010T3 (es) Composición farmacéutica mejorada que contiene un anticonvulsivante derivado de la pirrolidona y método para su preparación
JP2011500548A (ja) マンニトールおよび／または微結晶性セルロースを含むジボテンタン組成物
JP5775463B2 (ja) 溶出安定性製剤
JPWO2011102506A1 (ja) 経口用徐放性固形製剤
KR101438546B1 (ko) 프레가발린을 포함하는 서방성 제제
TWI859242B (zh) 嘧啶基胺基-吡唑化合物之修飾釋放調配物及治療方法
JP6116847B2 (ja) シクロデキストリンとの混合体を含有する錠剤
US20250352482A1 (en) Amorphous dosage form containing ebselen
JP2006510665A (ja) 新規な経口即時放出型投与剤形
ES2785398T3 (es) Composición farmacéutica que comprende Aripiprazol o sal del mismo
ES2868228T3 (es) Formas de dosificación farmacéuticas que contienen 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio
WO2023240092A1 (en) Ebselen containing oral dosage forms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140916